- Raised $46.5M funding round led by aMoon Fund, Jun 2021
- Raised $17.5M funding round, Jun 2023
- Raised $12.5M funding round, Nov 2022
About
KAHR is developing immuno-oncology drug candidates for the treatment of multiple types of cancer. Its lead product, DSP107, is a CD47x41BB targeting compound that simultaneously targets cancer cells, weakens their innate defenses, and activates an effective local response of both innate and adaptive immunity. KAHRs technology platform is based on multifunctional immuno-recruitment proteins (MIRP) that utilize overexpression of checkpoint antigens on cancer cells to selectively target and bind to the tumor. MIRPs bridge cancer cells to immune cells to produce a targeted synergistic effect by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response while recruiting the adaptive immune system to bind and selectively kill the cancer cells. In August 2020, KAHR Medical received FDA clearance to begin clinical trials on its immunotherapy drug to battle cancer.
Funding history · 12 rounds · $118.3M total
Q&A
- What is KAHR Medical's primary focus?
- KAHR Medical focuses on developing immuno-oncology drug candidates for treating various types of cancer and autoimmune diseases, utilizing fusion proteins.
- What is KAHR Medical's lead product?
- KAHR Medical's lead product is DSP107, a CD47x41BB targeting compound designed to target cancer cells, weaken their defenses, and activate both innate and adaptive immunity.
- When did KAHR Medical receive FDA clearance for clinical trials?
- In August 2020, KAHR Medical received FDA clearance to begin clinical trials for its immunotherapy drug aimed at battling cancer.
- What is KAHR Medical's total funding raised to date?
- KAHR Medical has raised a total of $118.27 million in funding.
- Which investors participated in KAHR Medical's June 2021 funding round?
- The June 2021 funding round for KAHR Medical included investments from aMoon Fund.
- When was KAHR Medical's most recent funding round with a disclosed amount?
- KAHR Medical's most recent funding round with a disclosed amount occurred in February 2024, raising $770,000 from Peregrine Ventures.
- What is the employee count for KAHR Medical?
- KAHR Medical has 11-50 employees.
- Where is KAHR Medical headquartered?
- KAHR Medical is headquartered in Modi'in-Maccabim-Re'ut, Israel.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | kahrbio.base44.app |
|---|---|
| linkedin.com/company/6724763 | |
| YouTube | youtube.com/channel/UCAHE_coSjQ1j76fTPMuJ0Yg |
Identifiers & details
| Founded | 2005-9 |
|---|---|
| Employees (exact) | 25 |
Radar intelligence
Patents
| EPO | 17 |
|---|
Web history (Wayback)
| Domain | kahrbio.base44.app |
|---|
Certificate / subdomain footprint
| Subdomains | 0 |
|---|